China's New Guideline For Drug Pricing Favors Innovation And First-to-market Generics
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - The National Development and Reform Commission, China's powerful economic regulatory body, is collecting feedback from industry for a new drug pricing guideline, which details new rules for setting drug prices in China's changing healthcare system